{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:29:09Z","timestamp":1746786549904,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women\u2019s Hospital."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40266-020-00745-2","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T03:02:56Z","timestamp":1580958176000},"page":"311-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Hemin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinzhu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miin","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore N.","family":"Tsacogianis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangshin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Kyong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3579","authenticated-orcid":false,"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"issue":"3","key":"745_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical practice: postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254\u201362.","journal-title":"N Engl J Med."},{"issue":"12","key":"745_CR2","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1359\/jbmr.2000.15.12.2309","volume":"15","author":"LJ Melton 3rd","year":"2000","unstructured":"Melton LJ 3rd. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res. 2000;15(12):2309\u201314.","journal-title":"J Bone Miner Res."},{"issue":"9319","key":"745_CR3","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761\u20137.","journal-title":"Lancet."},{"issue":"11","key":"745_CR4","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"S Khosla","year":"2017","unstructured":"Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898\u2013907.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"18","key":"745_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322.","journal-title":"N Engl J Med."},{"issue":"11","key":"745_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2165\/0002512-200825110-00007","volume":"25","author":"ED Deeks","year":"2008","unstructured":"Deeks ED, Perry CM. Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging. 2008;25(11):963\u201386.","journal-title":"Drugs Aging."},{"issue":"1","key":"745_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","volume":"13","author":"J Wu","year":"2018","unstructured":"Wu J, Zhang Q, Yan G, Jin X. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res. 2018;13(1):194.","journal-title":"J Orthop Surg Res."},{"issue":"3","key":"745_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/jbmr.3019","volume":"32","author":"NK Choi","year":"2017","unstructured":"Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J Bone Miner Res. 2017;32(3):611\u20137.","journal-title":"J Bone Miner Res."},{"issue":"3","key":"745_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339\u201351.","journal-title":"Lancet Oncol."},{"issue":"2","key":"745_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens, Greece). 2009;8(2):96\u2013110.","journal-title":"Hormones (Athens, Greece)"},{"issue":"2","key":"745_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","volume":"135","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003;135(2):219\u201322.","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"745_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ophtha.2012.10.028","volume":"120","author":"DV Patel","year":"2013","unstructured":"Patel DV, Horne A, House M, Reid IR, McGhee CN. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120(4):773\u20136.","journal-title":"Ophthalmology."},{"issue":"2","key":"745_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00198-014-2872-5","volume":"26","author":"DV Patel","year":"2015","unstructured":"Patel DV, Bolland M, Nisa Z, Al-Abuwsi F, Singh M, Horne A, et al. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int. 2015;26(2):499\u2013503.","journal-title":"Osteoporos Int."},{"issue":"7","key":"745_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.clon.2006.04.013","volume":"18","author":"TC Woo","year":"2006","unstructured":"Woo TC, Joseph DJ, Wilkinson R. Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol). 2006;18(7):545\u20136.","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"4","key":"745_CR15","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.4158\/EP11081.CR","volume":"17","author":"H Kaur","year":"2011","unstructured":"Kaur H, Uy C, Kelly J, Moses AM. Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract. 2011;17(4):e101\u20133.","journal-title":"Endocr Pract."},{"issue":"5","key":"745_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00198-019-04850-w","volume":"30","author":"LK Chehade","year":"2019","unstructured":"Chehade LK, Curragh D, Selva D. Bisphosphonate-induced orbital inflammation: more common than once thought? Osteoporos Int. 2019;30(5):1117\u201320.","journal-title":"Osteoporos Int."},{"issue":"2","key":"745_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","volume":"28","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Rothman KJ, Bateman BT, Hernandez-Diaz S, Huybrechts KF. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017;28(2):249\u201357.","journal-title":"Epidemiology."},{"issue":"12","key":"745_CR18","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00198-017-4175-0","volume":"28","author":"T Saito","year":"2017","unstructured":"Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int. 2017;28(12):3289\u2013300.","journal-title":"Osteoporos Int."},{"key":"745_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajo.2016.04.022","volume":"168","author":"Z Mammo","year":"2016","unstructured":"Mammo Z, Guo M, Maberley D, Matsubara J, Etminan M. Oral bisphosphonates and risk of wet age-related macular degeneration. Am J Ophthalmol. 2016;168:62\u20137.","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"745_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139(1):101\u201311.","journal-title":"Clin Exp Immunol."},{"issue":"8","key":"745_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/bjophthalmol-2013-303355","volume":"97","author":"C Or","year":"2013","unstructured":"Or C, Cui J, Matsubara J, Forooghian F. Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells. Br J Ophthalmol. 2013;97(8):1074\u20138.","journal-title":"Br J Ophthalmol."},{"key":"745_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/206837","author":"S Honda","year":"2010","unstructured":"Honda S, Nagai T, Kondo N, Fukuda M, Kusuhara S, Tsukahara Y, et al. Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye. J Ophthalmol. 2010. https:\/\/doi.org\/10.1155\/2010\/206837(Epub 2010 Jul 25).","journal-title":"J Ophthalmol."},{"issue":"5","key":"745_CR23","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1167\/iovs.02-0345","volume":"44","author":"D Tang","year":"2003","unstructured":"Tang D, Borchman D, Yappert MC, Vrensen GF, Rasi V. Influence of age, diabetes, and cataract on calcium, lipid-calcium, and protein\u2013calcium relationships in human lenses. Invest Ophthalmol Vis Sci. 2003;44(5):2059\u201366.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"1","key":"745_CR24","first-page":"444","volume":"17","author":"A Augoulea","year":"2017","unstructured":"Augoulea A, Tsakonas E, Triantafyllopoulos I, Rizos D, Armeni E, Tsoltos N, et al. Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. J Musculoskelet Neuronal Interact. 2017;17(1):444\u20139.","journal-title":"J Musculoskelet Neuronal Interact."},{"issue":"4","key":"745_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.12188","volume":"79","author":"P Makras","year":"2013","unstructured":"Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013;79(4):499\u2013503.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"8","key":"745_CR26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.2004.99.013","volume":"22","author":"TL Breen","year":"2004","unstructured":"Breen TL, Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol. 2004;22(8):1531\u20132.","journal-title":"J Clin Oncol."},{"issue":"7","key":"745_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437\u201341.","journal-title":"Nat Rev Rheumatol."},{"issue":"9","key":"745_CR28","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380\u20137.","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"745_CR29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ophtha.2003.12.052","volume":"111","author":"FW Fraunfelder","year":"2004","unstructured":"Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275\u20139.","journal-title":"Ophthalmology."},{"issue":"4","key":"745_CR30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5693\/djo.02.2017.08.002","volume":"23","author":"OC Umunakwe","year":"2017","unstructured":"Umunakwe OC, Herren D, Kim SJ, Kohanim S. Diffuse ocular and orbital inflammation after zoledronate infusion: case report and review of the literature. Digit J Ophthalmol. 2017;23(4):109\u201312.","journal-title":"Digit J Ophthalmol."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00745-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-020-00745-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00745-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:19:57Z","timestamp":1665760797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-020-00745-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00745-2","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"6 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Seoyoung C. Kim has received research grants to the Brigham and Women\u2019s Hospital from Pfizer, Roche, and Bristol-Myers Squibb for unrelated topics. Hemin Lee, Yinzhu Jin, Miin Roh, Theodore N. Tsacogianis, Sangshin Park, and Nam-Kyong Choi have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Personal identifiers were removed from the dataset before the analysis to protect subject confidentiality. Therefore, patient informed consent was not required. The study protocol was approved by the Institutional Review Board of Brigham and Women\u2019s Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This work is the sole product of the authors and has been presented at the 2018 International Conference on Pharmacoepidemiology and Therapeutic Risk Management.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior posting and presentation"}}]}}